Equities analysts expect Iqvia Holdings Inc (NYSE:IQV) to report earnings per share of $1.34 for the current fiscal quarter, Zacks Investment Research reports. Nine analysts have provided estimates for Iqvia’s earnings, with estimates ranging from $1.31 to $1.38. Iqvia posted earnings per share of $1.09 during the same quarter last year, which would indicate a positive year-over-year growth rate of 22.9%. The company is scheduled to report its next quarterly earnings results before the market opens on Wednesday, February 14th.
On average, analysts expect that Iqvia will report full-year earnings of $4.62 per share for the current fiscal year, with EPS estimates ranging from $4.59 to $4.66. For the next fiscal year, analysts anticipate that the firm will post earnings of $5.35 per share, with EPS estimates ranging from $5.15 to $5.53. Zacks’ earnings per share averages are a mean average based on a survey of sell-side research analysts that follow Iqvia.
Several equities research analysts recently weighed in on the company. SunTrust Banks reissued a “hold” rating and issued a $114.00 price objective on shares of Iqvia in a report on Friday, November 3rd. Jefferies Group lifted their price objective on Iqvia from $107.00 to $110.00 and gave the stock a “hold” rating in a report on Monday, October 30th. Zacks Investment Research lowered Iqvia from a “buy” rating to a “hold” rating in a report on Friday, November 3rd. Credit Suisse Group reissued an “outperform” rating and issued a $125.00 price objective (up previously from $115.00) on shares of Iqvia in a report on Tuesday, October 31st. Finally, Barclays lifted their price objective on Iqvia from $100.00 to $120.00 and gave the stock an “overweight” rating in a report on Friday, October 27th. Seven investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $109.71.
In other Iqvia news, insider James H. Erlinger III sold 10,000 shares of the firm’s stock in a transaction dated Wednesday, January 17th. The stock was sold at an average price of $99.97, for a total value of $999,700.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Ari Bousbib sold 46,080 shares of the firm’s stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $101.79, for a total value of $4,690,483.20. The disclosure for this sale can be found here. In the last 90 days, insiders sold 8,727,078 shares of company stock valued at $890,124,079. 6.40% of the stock is owned by corporate insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. New Mexico Educational Retirement Board bought a new stake in shares of Iqvia during the 4th quarter valued at about $1,429,000. Old Mutual Global Investors UK Ltd. bought a new stake in shares of Iqvia during the 4th quarter valued at about $675,000. ProVise Management Group LLC bought a new stake in shares of Iqvia during the 4th quarter valued at about $810,000. Private Advisor Group LLC bought a new stake in shares of Iqvia during the 4th quarter valued at about $307,000. Finally, Brookstone Capital Management bought a new stake in shares of Iqvia during the 4th quarter valued at about $258,000. Institutional investors and hedge funds own 95.79% of the company’s stock.
IQVIA Holdings Inc, formerly Quintiles IMS Holdings, Inc, provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.